Following is the text of a letter sent to the board of directors of Actelion (ATLN.VX), the Swiss biotechnology company, by Elliott Advisors, the hedge fund that is one of its biggest shareholders. For a Reuters story on Elliott's demands and Actelion's response, click [ID:nLDE7130KD] Dear Members of the Board of Directors, I write to you on behalf of Elliott Advisors (UK) Ltd. and its affiliates, one of your largest shareholders. We collectively own, or have an interest economically equivalent to, almost 6% of the share capital of Actelion Ltd (the "Company"). Elliott, founded in 1977, is a multi-strategy global investment firm with $17 billion in assets under management focused on employing detailed research to address complex investment situations and unlock shareholder value.
Source
